For the first time, a study by Advanced Cell Technology (“ACT”; OTCBB: ACTC)
Dr. Steven Schwartz, a retina specialist at the University of California, Los Angeles, conducted the trial with two patients. (Monica Almeida/The New York Times)
demonstrated the safety of the transplantation of human embryonic stem cells (hESC) derived from retinal pigment epithelium (RPE) into patients. Additionally, the injected cells survived and continued to persist during the study period. Results were reported for two patients, the first in each of the Phase 1/2 clinical trials, and were published in The Lancet, representing an important milestone for the field of embryonic stem cell research.
A patient said her vision improved in a meaningful way after the treatment, which used embryonic stem cells. (Monica Almeida/The New York Times)
In the study, patients with Stargardt’s macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD) were treated with ACT’s embryonic stem cell (ESC)-derived cells. Both patients were legally blind, and both had measurable improvements in their vision that persisted for more than four months. No treatments currently exist for either indication.
Through extensive media outreach coordinated by Russo Partners, coverage of this announcement was secured across all levels of print and broadcast media, including top tier, national, international, newswire, trade and regional outlets.
Below are links to samples of media coverage of the announcement:
New York Times
Los Angeles Times
Posted in Uncategorized
Tagged Advanced Cell Technology, AFP, Associated Press, BBC News, Bloomberg, CBS, CNN, Embryonic Stem Cells, FierceBiotech, hESC, Los Angeles Times, MedPage Today, Nature, New York Times, NPR, Reuters, Russo Partners, stem cells, The Lancet, The Scientist, The Telegraph, TIME, USA Today, WebMD
Press conference for OrbusNeich's late-breaking data
Last week in a late breaking session at Transcatheter Cardiovascular Therapeutics (TCT) 2011, OrbusNeich presented data for the company’s first-of-its-kind Combo Dual Therapy Stent, which combines a drug elution with the pro-healing healing GenousTM technology.
While the current standard of care for patients with coronary artery disease, drug eluting stents (DES), have reduced the risk of restenosis (narrowing of the artery), even the most advanced DES can cause delayed healing. The Combo Dual Therapy Stent is the first dual therapy stent to offer the best of both worlds, a stent combining pro-healing technology with a drug elution.
Data from the REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bioEngineered stEnt) trial demonstrated the safety and efficacy of the dual therapy stent (DTS) compared to a clinically proven DES. The primary end point of the study was in-stent late lumen loss at nine months, which is the difference in diameter of the stented area before and after the procedure.
Russo Partners was on-site in San Francisco to support and maximize awareness of OrbusNeich’s data announcement in the medical community. Our efforts included securing and coordinating in-person media interviews as well as the use of social media, utilizing Twitter to alert followers to OrbusNeich’s news releases and presentations.
We are excited by this promising data and the potential benefits it has for patients, and we are looking forward to additional data announcements from OrbusNeich when we can continue to provide guidance as well as support for their communications activities.
Below are examples of coverage generated from the data announcement:
Medical Device Daily
Posted in Uncategorized
Tagged Combo Dual Therapy Stent, coronary artery disease, drug eluting stent, Genous, healthcare, interventional cardiology, media relations, medical device, Medical Device Daily, MedPage Today, orbusneich, public relations, restenosis, Stent, TCT, Transcatheter Cardiovascular Therapeutics